Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic

Published: Tuesday, February 26, 2013
Last Updated: Monday, February 25, 2013
Bookmark and Share
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.

Lab21 Limited has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

Under the agreement, Lab21 will develop a CE marked assay, using its proprietary SPARQ™ PCR technology, to detect expression levels of a microRNA biomarker called hsa-mir-31-3p, which was discovered and patented by IntegraGen and its academic partners.

Early research with this biomarker has shown that it may predict response to EGFR inhibitor therapy in KRAS-wild type patients who have metastatic colorectal cancer. Financial details were not disclosed.

Most patients with metastatic colorectal cancer are currently screened and stratified by determining mutations in the KRAS gene.

Approximately 40% of these patients carry a KRAS mutation and are not candidates for EGFR inhibitor therapy.

Of the approximately 60% of patients who do not carry a KRAS mutation (i.e. KRAS wild type) and who are eligible for EGFR inhibitor therapy, effectiveness is still only 50-60%.

MicroRNA expression testing may provide a further level of stratification and thus aid clinicians to identify KRAS wild type patients most likely to respond to treatment: improving outcomes, avoiding adverse reaction and saving money in the healthcare system.

Graham Mullis, CEO of Lab21, commented: “We are delighted to enter into this assay development agreement with IntegraGen. Lab21’s experience in developing molecular diagnostics in the oncology and infectious disease settings is increasingly being recognized by major diagnostic manufacturers and pharmaceutical partners. The combination of our highly efficient assay development capability, regulatory and manufacturing know-how is actively being sought by developers of novel diagnostics, such as IntegraGen, who need partners to commercialize their biomarkers, including a route to market.”

Bernard Courtieu, CEO of IntegraGen, added: “We are pleased to be working with Lab21 to progress this biomarker towards commercialization in Europe. On the basis of good clinical results and regulatory approval we hope to have a CE Marked kit available based on Lab21’s technology by early 2014. With over 500,000 patients diagnosed with metastatic colorectal cancer annually on a global basis, there is a large market potential for an assay based on this biomarker.”

Following development of the assay, Lab21 and IntegraGen will explore other opportunities for partnerships relative to the manufacturing and commercialization of this novel oncology biomarker.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 Announces Sale of South Carolina Operations
Company announces sale of its laboratory operations to Reedy Acquisitions Corp.
Tuesday, April 23, 2013
Clydesdale Bank £5 Million Funding to Support Lab21 International Growth
Lab21 is expected to deliver greater than 30% revenue growth in 2012.
Tuesday, July 10, 2012
Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping
Company to expand its intellectual property portfolio in infectious disease testing.
Monday, May 21, 2012
Lab21 and ITOR Launch Clinical Genomics Center in USA
New Clinical Genomics Center will be located within the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, South Carolina.
Wednesday, March 07, 2012
Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Lab21 announces an agreement with ITOR to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
Wednesday, October 20, 2010
Lab21 Launches new Commercial Companion Diagnostic Service for HIV Tropism in UK
Company becomes the first commercial reference laboratory in the UK to provide a companion diagnostic service for the HIV drug, Celsentri.
Tuesday, August 31, 2010
Lab21 and BreastHealth UK Form Partnership for Breast Health Management
The partners will offer UK women personalized health management and predictive genetic testing for breast cancer risk.
Wednesday, February 04, 2009
Lab21 Expands Companion Diagnostic Cancer Testing Service Internationally
Lab21 now offer its K-RAS gene mutation and its epidermal growth factor receptor mutation testing services to its international customers.
Friday, July 18, 2008
Lab21 Expands Cancer Gene Testing Service
Lab21 has now added an epidermal growth factor receptor mutation test to its existing range.
Friday, June 27, 2008
Lab21 Launches Cancer Gene Testing Service
Lab21 is providing a test for analysis of the K-ras gene that plays an important role in cell growth regulation and the proliferation of cancer cells.
Friday, January 25, 2008
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!